Identification of Kidney Transplant Recipients with Coronavirus Disease 2019


Coronavirus disease 2019 (COVID-19) is a novel and lethal infectious disease, posing a threat to global health security. The number of cases has increased rapidly, but no data concerning kidney transplant (KTx) recipients infected with COVID-19 are available. To present the epidemiological, clinical, and therapeutic characteristics of KTx recipients infected with COVID-19, we report on a case series of five patients who were confirmed as having COVID-19 through nucleic acid testing (NAT) from January 1, 2020 to February 28, 2020. The most common symptoms on admission to hospital were fever (five patients, 100%), cough (five patients, 100%), myalgia or fatigue (three patients, 60%), and sputum production (three patients, 60%); serum creatinine or urea nitrogen levels were slightly higher than those before symptom onset. Four patients received a reduced dose of maintenance immunosuppressive therapy during hospitalization. As of March 4, 2020 NAT was negative for COVID-19 in three patients twice in succession, and their computed tomography scans showed improved images. Although greater patient numbers and long-term follow-up data are needed, our series demonstrates that mild COVID-19 infection in KTx recipients can be managed using symptomatic support therapy combined with adjusted maintenance immunosuppressive therapy.

Journal of Clinical Nephrology and Therapeutics  publishes scientific manuscripts that are directly or indirectly based on variegated aspects of clinical nephrology, diabetic nephropathy, pediatric nephrology, renal physiology, renal histopathology, immunobiology, intensive care nephrology and ischemic nephropathy.

The journal most specifically emphasizes on the propagation of research developments that may contribute in the furtherance of research and clinical implementation of novel tools as well as adept clinical techniques including renal transplantation, dialysis, diagnostic kidney imaging, aging and kidney disease, hemodialysis, body fluid volume composition, nephron endowment and erythropoietin therapy.

The journal accepts original submissions in the form of Research Articles, Review Articles, Short Communications, Opinion Articles, Case Reports and Commentaries. Acceptance or rejection of the manuscript solely depends upon the comments of independent reviewers. Positive review by at least two reviewers is mandatory for the acceptance and publication of any citable manuscript.

You may submit manuscripts as an email attachment to the following mail-id:

Kind Regards,
Mercedes Rose
Editorial Team
Journal of Clinical Nephrology and Therapeutic

WhatsApp: +44 1470-490003